The DOI matches its Crossref record.
Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans
Open accessAbstract
BACKGROUND: Group A meningococci are the source of major epidemics of meningitis in Africa. An affordable, highly immunogenic meningococcal A conjugate vaccine is needed. METHODS: We conducted two studies in Africa to evaluate a new MenA conjugate vaccine (PsA-TT). In study A, 601 children, 12 to 23 months of age, were randomly assigned to receive PsA-TT, a quadrivalent polysaccharide reference vaccine (PsACWY), or a control vaccine (Haemophilus influenzae type b conjugate vaccine [Hib-TT]). Ten months later, these children underwent another round of randomization within each group to receive a full dose of PsA-TT, a one-fifth dose of PsACWY, or a full dose of Hib-TT, with 589 of the original participants receiving a booster dose. In study B, 900 subjects between 2 and 29 years of age were randomly assigned to receive PsA-TT or PsACWY. Safety and reactogenicity were evaluated, and immunogenicity was assessed by measuring the activity of group A serum bactericidal antibody (SBA) with rabbit complement and performing an IgG group A-specific enzyme-linked immunosorbent assay. RESULTS: In study A, 96.0% of the subjects in the PsA-TT group and 63.7% of those in the PsACWY group had SBA titers that were at least four times as high as those at baseline; in study B, 78.2% of the subjects in the PsA-TT group and 46.2% of those in the PsACWY group had SBA titers that were at least four times as high as those at baseline. The geometric mean SBA titers in the PsA-TT groups in studies A and B were greater by factors of 16 and 3, respectively, than they were in the PsACWY groups (P<0.001). In study A, the PsA-TT group had higher antibody titers at week 40 than the PsACWY group and had obvious immunologic memory after receiving a polysaccharide booster vaccine. Safety profiles were similar across vaccine groups, although PsA-TT recipients were more likely than PsACWY recipients to have tenderness and induration at the vaccination site. Adverse events were consistent with age-specific morbidity in the study areas; no serious vaccine-related adverse events were reported. CONCLUSIONS: The PsA-TT vaccine elicited a stronger response to group A antibody than the PsACWY vaccine. (Funded by the Meningitis Vaccine Project through a grant from the Bill and Melinda Gates Foundation; Controlled-Trials.com numbers, ISRCTN78147026 and ISRCTN87739946.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Vaccines for the twenty-first century society
Rappuoli, R., Mandl, C. W., Black, S., & De Gregorio, E. (2011) · Nature Reviews Immunology · doi:10.1038/nri3085 · Cited by 388
Effect of vaccines on bacterial meningitis worldwide
McIntyre, P. B., O'Brien, K. L., Greenwood, B., & van de Beek, D. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61187-8 · Cited by 326
The changing and dynamic epidemiology of meningococcal disease
Halperin, S. A., Bettinger, J. A., Greenwood, B., Harrison, L. H., Jelfs, J., Ladhani, S. N., McIntyre, P., Ramsay, M. E., & Sáfadi, M. A. P. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.032 · Cited by 307
Metadata
- Authors
- Sow, S. O., Okoko, B. J., Diallo, A., Viviani, S., Borrow, R., Carlone, G., Tapia, M., Akinsola, A. K., Arduin, P., Findlow, H., Elie, C., Haidara, F. C., Adegbola, R. A., Diop, D., Parulekar, V., Chaumont, J., Martellet, L., Diallo, F., Idoko, O. T., Tang, Y., Plikaytis, B. D., Kulkarni, P. S., Marchetti, E., LaForce, F. M., & Preziosi, M.-P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-16
- Volume
- 364
- Issue
- 24
- Pages
- 2293-2304
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2038976319
- Cited by
- 178
- References
- 0
- FWCI
- 24.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans. https://app.cochat.ai/papers/10.1056/nejmoa1003812
- The paper
- Sow, S. O., Okoko, B. J., Diallo, A., Viviani, S., Borrow, R., Carlone, G., Tapia, M., Akinsola, A. K., Arduin, P., Findlow, H., Elie, C., Haidara, F. C., Adegbola, R. A., Diop, D., Parulekar, V., Chaumont, J., Martellet, L., Diallo, F., Idoko, O. T., . . . Preziosi, M.-P. (2011). Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1003812
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.